Tidal Trust II YieldMax MSTR Option Income Strategy ETF (ARCA: MSTY)

Latest news for Tidal Trust II YieldMax MSTR Option Income Strategy ETF (ARCA:MSTY)

The Fund is an actively managed exchange-traded fund (ETF) that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of MicroStrategy Incorporated (MSTR), subject to a limit on potential investment gains. The Fund will seek to employ its investment strategy as it relates to MSTR regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. As further described below, the Fund uses a synthetic covered call strategy to provide income and exposure to the share price returns of MSTR, subject to a limit on potential investment gains as a result of the nature of the options strategy it employs.

First American Government Obligations Fund

YieldMax MSTR Option Income Strategy ETF

Tidal Trust II YieldMax MSTR Option Income Strategy ETF

As Thanksgiving approaches, the Last Prisoner Project (LPP) called on President Biden to fulfill his promise that "no one should be in jail for marijuana" by granting clemency to individuals still incarcerated for nonviolent cannabis offenses.
The non-profit cannabis justice reform organization reminded that there's only two months remaining in the <a href="https://www.benzinga.com/markets/cannabis/24/09/40805469/biden-faces-pressure-to-release-thousands-imprisoned-for-federal-cannabis-convictions">#Countdown4Clemency campaign</a>, and that an impending change in administration highlights the urgency for President to take action.
LPP stressed that Biden has <a href="https://www.benzinga.com/markets/cannabis/24/09/40885403/biden-has-not-freed-anyone-in-prison-for-cannabis-crime-last-prisoner-project-urges-president-to">not released a single person</a> still incarcerated for cannabis through commutation. While his <a href="Biden Pardons Thousands Convicted Of Cannabis Possession, Calls On Governors To Do The Same">categorical pardons</a> provided record relief to thousands of people with cannabis possession convictions, this move alone does not address the estimated 3,000 people still serving time in federal prisons for cannabis offenses.
Ahead of the annual presidential tradition of pardoning turkeys, LPP is asking President Biden to #PardonPeopleNotPoultry and end the continued incarceration of thousands for cannabis-related offenses that are now legal in many states.
A YouGov poll released in August indicated that cannabis pardons was one of the most popular policies of Biden's entire administration. Meanwhile, polls show that 84% of registered voters favor releasing people still in prison when their convictions are no longer considered crimes, like cannabis-related offenses.
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Governors Took Action</h2>
At the state level, Kansas Governor Laura Kelly was the first to kick off the holiday clemency season granting clemency last week to LPP constituent Deshaun T. Durham, a 24-year-old who was sentenced to 92 months for a first-time cannabis offense, setting a powerful precedent for others to follow. Other recent actions by state leaders like Massachusetts Governor <a href="https://www.benzinga.com/markets/cannabis/24/04/38101290/gov-healeys-mega-pardon-for-cannabis-possession-unanimously-approved-by-council">Maura Healey</a> and Maryland Governor Wes Moore, who used LPP's #PenToRightHistory <a href="https://www.benzinga.com/markets/cannabis/24/06/39357557/maryland-gov-to-pardon-175k-low-level-cannabis-convictions-in-the-nations-most-far-reaching-and-">to pardon over 175,000 individuals</a> for cannabis-related charges, highlight the growing momentum for cannabis clemency.
<h2 class="wp-block-heading">More Still Behind Bars</h2>
Yet, for other Marylanders like Jonathan Wall, incarcerated on an 8-year federal cannabis charge, can only get that type of clemency relief from the president. Then, there's Ricardo Ashmeade, who is serving a 22-year sentence due to the three-strikes law championed by then-Senator Biden. His daughter, Richeda Ashmeade, has been separated from her father for 16 years. In addition to Ricardo, individuals like Edwin Rubis, who is serving a 40-year sentence for a cannabis-related offense, and David Lopez, who has faced years behind bars for court errors on his cannabis charges, exemplify the urgent need for clemency.
Read More: <a href="https://www.benzinga.com/markets/cannabis/24/09/40869663/meet-the-man-serving-a-40-year-sentence-for-non-violent-cannabis-charges-awaiting-pardon-from-bi">Meet The Man Serving A 40-Year Sentence For Non-Violent Cannabis Charges, Awaiting Pardon From Biden</a>
Along with its 420 Unity Coalition partners, LPP will hold a press conference in Washington D.C. next week to encourage people to call President Biden to urge him to reunite these families before the holidays and send letters to the White House to grant cannabis clemency before the end of his term.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41008113/white-house-highlights-marijuana-pardons-amid-skepticism-over-cannabis-rescheduling-efforts">White House Highlights Marijuana Pardons Amid Skepticism Over Cannabis Rescheduling Efforts</a></li>
</ul>
Photo: Benzinga edit Adam Schultz on Wikimedia Commons and David Smart on Shutterstock

Cannabis

News

President Biden, People Are Still In Jail For Marijuana Despite Your Promise, Cannabis Clemency Advocates Call For Change

Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.66 by 30.3 percent. This is a 72.62 percent decrease over earnings of $1.68 per share from the same period last year. The company reported quarterly sales of $1.08 billion which missed the analyst consensus estimate of $1.09 billion by 0.93 percent. This is a 41.47 percent decrease over sales of $1.84 billion the same period last year.

Earnings

Sociedad Quimica Y Minera Q3 EPS $0.46 Misses $0.66 Estimate, Sales $1.08B Miss $1.09B Estimate

B. Riley Securities analyst Dave Kang downgrades Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) from Neutral to Sell and lowers the price target from $194 to $178.

Downgrades

Price Target

Analyst Ratings

B. Riley Securities Downgrades Fabrinet to Sell, Lowers Price Target to $178

WIIM

XTKG

X3 Holdings shares are trading lower. The company announced a 1-for-20 reverse stock split.

SLXN

Silexion Therapeutics shares are trading higher after the company announced Guangzhou Sino-Israel bio-industry investment fund reported a 13.8% stake in the company.

Barclays analyst Saket Kalia maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Overweight and raises the price target from $42 to $51.

RBRK

Barclays Maintains Overweight on Rubrik, Raises Price Target to $51

LuxUrban Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.01) by 2300 percent. This is a 318.18 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $13.13 million which missed the analyst consensus estimate of $28.05 million by 53.18 percent. This is a 57.92 percent decrease over sales of $31.21 million the same period last year.

LUXH

LuxUrban Hotels Q3 EPS $(0.24) Misses $(0.01) Estimate, Sales $13.13M Miss $28.05M Estimate

Events

CGON

CG Oncology To Present At Society of Urologic Oncology (SUO) 25th Annual Meeting Dec. 4-6

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) will discuss its strategic priorities and long-term financial commitments with the investment community today at <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42084062/delta-highlights-differentiation-durability-at-2024-investor-day" rel="noreferrer noopener">2024 Investor Day in New York.</a>
&#8220;We are introducing a three-to-five-year financial framework across key value drivers including margin expansion, durable earnings and free cash flow, and balance sheet strength that reflect Delta&#8217;s financial discipline and strategic priorities,&#8221; commented Delta CFO Dan Janki.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/travel/24/11/42014787/delta-united-alaska-air-are-top-analyst-picks-in-airline-sector" rel="noreferrer noopener">Delta, United, Alaska Air Are Top Analyst Picks In Airline Sector</a>
Delta&#8217;s three-to-five-year financial framework targets mid-teens operating margins, 10% average annual EPS growth, and $3-5 billion in annual free cash flow. With 1x gross leverage, 15%+ return on invested capital, and $40 billion in unencumbered assets, the framework emphasizes margin expansion, durable earnings, and balance sheet strength.
Delta&nbsp;also reaffirmed its expected <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41270201/deltas-turbulent-q3-mixed-results-and-tech-troubles-cloud-holiday-outlook" rel="noreferrer noopener">fourth-quarter financial guidance</a>. On a non-GAAP basis, the company expects revenue growth of 2% – 4%, EPS of $1.60 – $1.85 versus $1.74 consensus, and an operating margin of 11% &#8211; 13%.
The company also provided preliminary commentary on 2025 for capacity growth of three to four percent year-over-year, revenue growth of mid-single digits and non-fuel unit cost growth of low-single digits year-over-year.&nbsp;
Price Action: DAL shares are trading higher by 0.39% at $65.00 premarket at the last check Wednesday.
Photo via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42076876/what-could-trumps-new-dot-pick-mean-for-evs-airlines-railroads" target="_blank" rel="noreferrer noopener">What Trump&#8217;s DOT Pick Could Mean For EVs, Airlines, Railroad Stocks</a></li>
</ul>

Equities

Guidance

Delta Charts Path To High Margins And Shareholder Gains At 2024 Investor Day

Quantum-Si shares are trading higher after the company announced a distribution agreement with Avantor for next-generation protein sequencing portfolios for researchers.

Raymond James analyst Danielle Brill initiates coverage on Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) with a Outperform rating and announces Price Target of $65.

Initiation

TECX

Raymond James Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $65

-Strategic initiative would provide LuxUrban with a $7 million initial capital infusion, offering the opportunity to broaden its market impact representing a key milestone in building Lux 2.0
-Joint venture would leverage advanced technology integration to streamline operations, elevate service offerings, and deliver an enhanced guest experience
MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>), a hospitality company that leases entire hotels on a long-term basis, manages these hotels, and rents out rooms to guests in the properties it leases, today announced the signing of a Non-Binding Letter of Intent (LOI) with Lockwood Development Partners LLC and The Bright Hospitality Management, LLC proposing to establish a joint venture ("JV") focused on hotel services and operations.
The joint venture would initially focus on two LuxUrban properties in New York City, with the parties to consider expansion of the relationship to include additional LuxUrban hotels based on the success of the initiative. The collaboration would leverage Lockwood's established presence in hotel development and Bright's innovative hospitality technology to create a unique guest experience and optimize operational efficiencies.
Key Highlights of the Joint Venture:
Initial Capital Investment: Lockwood would initially invest approximately $7 million to address obligations and enhance facilities in the initial two JV hotels, with potential additional investments reaching up to $35 million if all existing LuxUrban hotels are later added to the JV structure.

Contracts

LuxUrban Hotels Signs A Non-Binding LOI For Proposed Joint Venture With Lockwood Development Partners LLC And The Bright Hospitality Management To Elevate Hotel Operations And Guest Experience; Strategic Initiative Would Provide LuxUrban With A $7M Initial Capital Infusion, Offering The Opportunity To Broaden Its Market Impact Representing A Key Milestone In Building Lux 2.0

Wix.com shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue guidance. Also, multiple firms raised their respective price targets on the stock.

Genius Group Sees Prelim. 1H Revenue $13.2M vs $11.8M YoY; Sees Prelim. 1H Pro Forma Revenue $20.7M vs $9M YoY

Barclays analyst Tim Long maintains Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) with a Overweight and raises the price target from $180 to $200.

KEYS

Barclays Maintains Overweight on Keysight Techs, Raises Price Target to $200

DUOT

Duos Technologies Secures $42M Asset Management Deal With Fortress To Oversee 850MW Mobile Gas Turbine Portfolio, Targeting Deployment For U.S. Data Centers And Global Power Projects

Pivotal Research analyst Jeffrey Wlodarczak maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and raises the price target from $925 to $1100.

NFLX

Pivotal Research Maintains Buy on Netflix, Raises Price Target to $1100

Dynatrace integrates with Microsoft security technology to enhance cloud security for customers
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dynatrace.com%2F&amp;esheet=54155433&amp;newsitemid=20241120414876&amp;lan=en-US&amp;anchor=Dynatrace&amp;index=1&amp;md5=d6e91ac491e18743dbdd4bb3bfbcb642">Dynatrace</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) has become a member of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faka.ms%2FMISA&amp;esheet=54155433&amp;newsitemid=20241120414876&amp;lan=en-US&amp;anchor=Microsoft+Intelligent+Security+Association+%28MISA%29&amp;index=2&amp;md5=63446b9c4e4e83e7483fff7e054d85a7">Microsoft Intelligent Security Association (MISA)</a> to provide customers with enhanced cloud security solutions through continuous innovation and collaboration with Microsoft and other MISA members. MISA is an ecosystem of independent software vendors (ISVs) and managed security service providers (MSSPs) that have integrated their solutions with Microsoft security technology to better defend mutual customers against cyber threats, which are rapidly increasing. According to recent Dynatrace research, nearly <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dynatrace.com%2Finfo%2Freports%2Fciso-report-state-of-application-security%2F&amp;esheet=54155433&amp;newsitemid=20241120414876&amp;lan=en-US&amp;anchor=72%25+of+CISOs+have+faced+application+security+incidents+in+the+past+two+years&amp;index=3&amp;md5=e6d21a2b776a415778f4648c77b9f5c4">72% of CISOs have faced application security incidents in the past two years</a>.
Dynatrace was nominated to MISA because of its powerful integration with Microsoft's SIEM solution, Microsoft Sentinel. Dynatrace delivers comprehensive observability and security, offering vital insights that simplify cloud complexity and empower organizations to proactively combat evolving cyber threats. By merging the insights from Dynatrace with Microsoft Sentinel, organizations gain a more holistic understanding of their security posture. As a result, SecOps teams can detect application attack attempts more effectively, streamline incident management, and proactively mitigate issues as part of their efforts to keep their cloud-native environments secure and their business operations resilient.

Dynatrace Integrates With Microsoft Security Technology To Enhance Cloud Security For Customers

Williams-Sonoma shares are trading higher after the company reported better-than-expected Q3 financial results. Also, the company approved a $1 billion stock repurchase authorization.

French biotech company Aelis Farma, specializing in the treatment of brain disorders announced positive results Monday from a <a href="https://www.benzinga.com/markets/cannabis/22/11/29769327/aelis-farmas-drug-candidate-for-the-treatment-of-cognitive-disorders-authorized-for-the-first-tr">Phase 1/2 trial of its drug candidate AEF0217</a> in young adults with Down syndrome. The study, conducted in Spain, assessed the safety, tolerability and potential efficacy of AEF0217, a selective CB1 receptor inhibitor targeting cognitive and behavioral impairments.
The study successfully met its safety (primary), pharmacokinetics (secondary) and efficacy (secondary and exploratory) objectives. AEF0217 was well tolerated and no safety concerns were observed. The drug improved adaptive behavior in areas such as communication, daily living skills and socialization.
"The promising and impressive results of this study generate a real hope to develop an efficacious and safe treatment for the cognitive disabilities of people with Down syndrome," stated Prof. Rafael de la Torre Fornell, the trial's principal investigator. "Particularly striking are the efficacy data, which addresses crucial domains of adaptation, such as expression and writing abilities as well as certain daily living skills and societal interactions. These types of effects, especially because obtained after only four weeks of treatment, are certainly a first in the field of Down syndrome and represent a major step towards the development of a treatment that could significantly improve the autonomy and adaptation of people with Down syndrome. I would like to take this occasion to also send my warmest thanks to the participants, their families and family associations who supported this innovative project and helped us to complete this pioneering clinical trial."
It is noteworthy that AEF0217 seemed to induce larger improvements in participants with the greater impairments before starting the treatment.
Moreover, adaptive behavior and cognition were assessed after just four weeks of treatment, whereas experts generally believe several months are needed to modify these functions in neurodevelopmental disabilities.
Read Also: <a href="http://a/">Can THC Turn Back The Clock? Cannabis Reverses Brain Aging, Boosts Mental Capacity, New Study Suggests</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Paving The Way For Treating Other Cognitive Disorders</h2>
Pier Vincenzo Piazza, CEO of Aelis Farma, concluded, "We see this accomplishment as a milestone in the development of a promising therapy that could significantly improve the autonomy and quality of life of people with Down syndrome. It is also, more generally, the first evidence of the positive impact of AEF0217 on cognition, which could pave the way for the treatment of other cognitive disorders."
Piazza also highlighted that these results offer a supplementary validation of the safety of the new pharmacological class developed by the company &#8211; Signaling Specific inhibitors of the CB1 receptor (CB1-Ssi). "We believe that the CB1-SSi represent a major innovation in pharmacology that will allow to generate inhibitors not only efficacious but also safe and well tolerated, opening the way to new treatments of conditions without treatment today," he concluded.
Following these results, Aelis Farma plans a Phase 2 international study in 2025 to further evaluate its efficacy and adaptative behavior improvements.
The clinical development of AEF0217, the phase 1 program in healthy volunteers, the phase 1/2 just completed and the next phase 2 in people with Down syndrome are part of the European H2020 ICOD project (Improving COgnition in Down syndrome, Grant Agreement ID 899986). The ICOD project received €6 million ($6.33 million) of fundings from the European Commission and involves partners in Spain, France and Italy.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40722274/french-biotech-candidate-for-cannabis-use-disorder-fails-phase-2b-clinical-trial-indivior-will-n">French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option</a>
Photo generated with AI

After Four Weeks, New Drug Shows Promising Results In Boosting Life Skills For Down Syndrome Patients

Yieldmax MSTR Option Income Strategy ETF declares $1.8541 dividend

YMAX: Weakness Of Strategy On Full Display

IBIT Options Approval: Massive Watershed Moment For Bitcoin

MSTY: Risk Masquerading As Income

Avoid YMAX: High Fees And Bad Strategy

MSTY: A Monthly Income Machine Fueled By MicroStrategy's Volatility

Yieldmax MSTR Option Income Strategy ETF declares $4.198 dividend

Is MicroStrategy Tapped Out? Long BTC, Short MSTR Isn't As Smart As You Think

MSTY: The 200% Distribution Rate Makes Me Nervous

YMAX: Is This 43% Dividend Yield Sustainable?

ABNY

APLY

BITO

CONY

FBTC

GOOY

IBIT

JEPI

JEPQ

MSTR

MSTU

MSTX

MSTY

NFLY

NVDY

PYPY

QYLD

TSLY

ULTY

YMAX

Press Releases

YieldMax™ Launches Option Income Strategy ETF on MicroStrategy (MSTR)

Comments

Tidal Trust II YieldMax MSTR Option Income Strategy ETF

News

Latest news for Tidal Trust II YieldMax MSTR Option Income Strategy ETF (ARCA:MSTY)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga